Amyotrophic Lateral Sclerosis (ALS) - Market Insight, Epidemiology and Market Forecast -2027

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 11/26/2018 -- DelveInsight has announced the addition of the "Amyotrophic Lateral Sclerosis (ALS) - Market Insight, Epidemiology and Market Forecast -2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of ALS for the seven major markets i.e., the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan. The Report covers the overview, treatment practice and ALS forecasted epidemiology from 2018 to 2027 segmented by the seven major markets.

Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a wider group of disorders known as motor neuron diseases, which are caused by gradual deterioration (degeneration) and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body. These motor neurons initiate and provide vital communication links between the brain and the voluntary muscles.

The disease is 20% more common in men than in women. The people, who develop ALS are between the ages of 40 and 70, with an average age of 55 at the time of diagnosis. However, cases of the disease do occur in persons in their twenties and thirties. With increasing age, the incidence of ALS is more equal between men and women. The ratio of cases in males to those in females was 1.7:1.

Geography Covered
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies
1. Cytokinetics
2. Orphazyme
3. Orion
4. Brainstorm Cell Therapeutics
5. Astellas Pharma
And many others

Drugs covered
1. ODM-109
2. Reldesemtiv
3. Arimoclomol
4. NurOwn
5. Acthar
And many others

Report Scope
The report covers a descriptive overview of the ALS, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the ALS and its treatment in the 7 MM, covering the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for ALS are provided, along with an assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted ALS market is included in the report, covering drug outreach in the 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global ALS market.

For more information on this press release visit: http://www.sbwire.com/press-releases/amyotrophic-lateral-sclerosis-als-market-insight-epidemiology-1091705.htm